Thanks for the citation.
Well, Mesoblast Ltd shareholders should be quaking in their boots about this one.....
I've set out below an extract from the opinion and order made in [Rel. 20-CV-09111 (PMH)] by PHILIP M. HALPERN, United States District Judge. The good judge, in making the order to consolidate the claims against Mesoblast Ltd in the New York actions, in part said this:
So, this monstrously huge case is what the AFR has been beating up Mesoblast Ltd with in the Australian share market. Wow.
To reiterate - the greatest financial loss claimed was approx. US$60,230. So, the biggest after-tax cost to Mesoblast Ltd's balance sheet is apparently mostly the NY lawyers fees in filing & defending.
No wonder Australian companies have difficulty getting offshore - the 'tall poppy' syndrome in this country is a killer. And the lack of journalistic talent can only be explained in terms of a complete unwillingness to conduct scientific, or even reliable, factual research
Cell Therapy News/Articles, page-9853
-
- There are more pages in this discussion • 8,393 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.035(3.21%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.07 | $3.910M | 3.535M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 27197 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 43578 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |